Aptar Pharma, a leading provider of innovative drug delivery systems, in combination with Schott Glass and EMA Pharmaceuticals, has announced that it will launch Aptar Pharma QuickStart™ for injectable drug development at CPhI Worldwide 2018, in Madrid, Spain, October 9th.
Aptar Pharma QuickStart™ is a sterile, Ready-To-Use (RTU) drug development support kit designed specifically for research & development labs. A package complete with glass vials, elastomeric stoppers and caps, QuickStart™ provides everything needed for the small volume filling of high value formulations. Also included in the kit are all the quality and technical documentation required to verify the sterilization and compatibility (CCI) of components.
Co-developed alongside Schott and EMA Pharmaceuticals, Aptar Pharma QuickStart™ is available to cater to different sizes and configurations of vials, stoppers and caps.
Aptar Pharma’s proven expertise in device development and formulation helps ensure that QuickStart™’s components satisfy all regulatory requirements, allowing users to access commercial scale quality at a development stage cost.
CPhI Worldwide, which takes place October 9-11, 2018 at IFEMA, Feria de Madrid, will welcome more than 45,000 pharma professionals, which provides a prime opportunity to demonstrate the value of Aptar Pharma QuickStart™ to prospective partners.
Adam Shain, Aptar Pharma’s Director, Global Business Development – Injectables, comments, “We are excited to be launching Aptar Pharma QuickStart™ at CPhI Worldwide, a solution which we are confident will accelerate pharma companies’ bench-to-market.
QuickStart™ is all about convenience and speed by enabling R&D labs to maintain a positive development experience from project outset, including the ability to control the component configuration in terms of coating, volume and size, and that the integrity of the container closure for delivery mechanisms can be maintained.”
Luce Sohier, SCHOTT, Business Development adds, “We appreciate that the SCHOTT Topline Vials were choosen to be part of Aptar Pharma QuickStart™. We share the vision that enabling our customers to expedite their reseach is critical. We also see as a real asset that we are providing our customers with the neccessary quality documentation for regulatory filing.”
Stefan Greife, Sales Director of EMA Pharmaceuticals concludes, “We are very proud to be part of this collaboration for the launch of QuickStart™, providing our customers with a robust, easy-to-use solution.”
Visit Aptar Pharma at CPhI at stand 4D10, Hall 4 to find out more about Aptar Pharma QuickStart™ and Aptar Pharma’s broad range of innovative drug delivery systems.
About Aptar Pharma
Aptar Pharma is part of AptarGroup, Inc., a leading global supplier of a broad range of innovative dispensing and sealing solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets. AptarGroup is headquartered in Crystal Lake, Illinois, with manufacturing facilities in North America, Europe, Asia and South America. For more information, visit aptar.com/pharma.
SCHOTT is a leading international technology group in the areas of specialty glass and glass-ceramics. The company has more than 130 years of outstanding development, materials and technology expertise and offers a broad portfolio of high-quality products and intelligent solutions. SCHOTT is an innovative enabler for many industries, including the home appliance, pharma, electronics, optics, life sciences, automotive and aviation industries. SCHOTT strives to play an important part of everyone’s life and is committed to innovation and sustainable success. With more than 15,500 employees at production sites
and sales offices in 33 countries, the group has a global presence. In the 2016/2017 fiscal year, SCHOTT generated sales of $2.26 billion. For more nformation, visit www.schott.com
About EMA Pharmaceuticals
With almost a century of experience, EMA Pharmaceuticals is a leader in the manufacturing of sealing solutions for pharmaceutical applications.Solely dedicated to the pharmaceutical industry, EMA Pharmaceuticals currently serves more than 170 production sites of injectable medicine across the world. For more information, visit www.emapharma.com